Virus-like particles: flexible platforms for vaccine development

References

• Warzecha H, Mason HS, Lane C et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J. Virol.77(16), 8702–8711 (2003).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA89(24), 12180–12184 (1992).
   PubMed Web of Science ®Google Scholar
• Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J. Virol.78(2), 751–757 (2004).
   PubMed Web of Science ®Google Scholar
• Hofmann K, Cook J, Joyce J et al. Sequence determination of human papillomavirus 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology209, 506–518 (1995).
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Roden RBS, Benyacoub J et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun.65, 3328–3336 (1997).
   PubMed Web of Science ®Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods40(1), 60–65 (2006).
   PubMed Web of Science ®Google Scholar
• Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol.107(1), 18–27 (2006).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med.336(26), 1855–1859 (1997).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science262(5138), 1448–1451 (1993).
   PubMed Web of Science ®Google Scholar
• Fehr T, Skrastina D, Pumpens, P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl Acad. Sci. USA95(16), 9477–9481 (1998).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu. Rev. Immunol.15, 235–270 (1997).
   PubMed Web of Science ®Google Scholar
• Thyagarajan R, Arunkumar N, Song W. Polyvalent antigens stabilize B cell antigen receptor surface signaling microdomains. J. Immunol.170(12), 6099–6106 (2003).
   PubMed Web of Science ®Google Scholar
• Brunswick M, Finkelman FD, Highet PF, Inman JK, Dintzis HM, Mond JJ. Picogram quantities of anti-Ig antibodies coupled to dextran induce B cell proliferation. J. Immunol.140(10), 3364–3372 (1988).
   PubMed Web of Science ®Google Scholar
• Dintzis HM, Dintzis RZ, Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc. Natl Acad. Sci. USA73(10), 3671–3675 (1976).
   PubMed Web of Science ®Google Scholar
• Dintzis RZ, Middleton MH, Dintzis HM. Inhibition of anti-DNP antibody formation by high doses of DNP-polyacrylamide molecules; effects of hapten density and hapten valence. J. Immunol.135(1), 423–427 (1985).
   PubMed Web of Science ®Google Scholar
• Milich DR, Chen M, Schodel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl Acad. Sci. USA94(26), 14648–14653 (1997).
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst.93(4), 284–292 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang LF, Zhou J, Chen S et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine18(11–12), 1051–1058 (2000).
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol.173(5), 3148–3154 (2004).
   PubMed Web of Science ®Google Scholar
• Moron G, Rueda P, Casal I, Leclerc C. CD8α- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8α and CD205 molecules. J. Exp. Med.195(10), 1233–1245 (2002).
   PubMed Web of Science ®Google Scholar
• Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today17(3), 131–137 (1996).
   PubMedGoogle Scholar
• Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA90(11), 4942–4946 (1993).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Lutz MB, Layton GT et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur. J. Immunol.26, 2595–2600 (1996).
   PubMed Web of Science ®Google Scholar
• Lenz P, Day PM, Pang YY et al. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol.166(9), 5346–5355 (2001).
   PubMed Web of Science ®Google Scholar
• Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol.166(10), 5917–5924 (2001).
   PubMed Web of Science ®Google Scholar
• Tsunetsugu-Yokota Y, Morikawa Y, Isogai M et al. Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs. J. Virol.77(19), 10250–10259 (2003).
   PubMed Web of Science ®Google Scholar
• Bosio CM, Moore BD, Warfield KL et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology326(2), 280–287 (2004).
   PubMed Web of Science ®Google Scholar
• Moron G, Dadaglio G, Leclerc C. New tools for antigen delivery to the MHC class I pathway. Trends Immunol.25(2), 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Schodel F, Wirtz R, Peterson D et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med.180(3), 1037–1046 (1994).
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Tissot A, Lechner F et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine20(25–26), 3104–3112 (2002).
   PubMed Web of Science ®Google Scholar
• Karpenko LI, Ivanisenko VA, Pika IA et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids18(4), 329–337 (2000).
   PubMed Web of Science ®Google Scholar
• Billaud JN, Peterson D, Barr M et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J. Virol.79(21), 13656–13666 (2005).
   PubMed Web of Science ®Google Scholar
• Kratz PA, Bottcher, B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl Acad. Sci. USA96(5), 1915–1920 (1999).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Rangel M, Hunter Z, Peabody DS. Virus and virus-like particle-based immunogens for Alzheimer’s disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine24(37–39), 6321–6331 (2006).
   PubMed Web of Science ®Google Scholar
• Li Q, Cao C, Chackerian B et al. Overcoming antigen masking of anti-amyloid β antibodies reveals breaking of B cell tolerance by virus-like particles in amyloid β immunized amyloid precursor protein transgenic mice. BMC Neurosci.5(1), 21 (2004).
   PubMedGoogle Scholar
• Wang Q, Lin T, Johnson JE, Finn MG. Natural supramolecular building blocks. Cysteine-added mutants of cowpea mosaic virus. Chem. Biol.9(7), 813–819 (2002).
   PubMed Web of Science ®Google Scholar
• Peabody DS. A viral platform for chemical modification and multivalent display. J. Nanobiotechnology1(1), 5 (2003).
   PubMedGoogle Scholar
• Rohn TA, Jennings GT, Hernandez M et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol.36(11), 2857–2867 (2006).
   PubMed Web of Science ®Google Scholar
• Raja KS, Wang Q, Gonzalez MJ, Manchester M, Johnson JE, Finn MG. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules4(3), 472–476 (2003).
   PubMed Web of Science ®Google Scholar
• Maurer P, Jennings GT, Willers J et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol.35(7), 2031–2040 (2005).
   PubMed Web of Science ®Google Scholar
• Stockwin LH, Holmes S. Antibodies as therapeutic agents: vive la renaissance! Expert Opin. Biol. Ther.3(7), 1133–52 (2003).
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods36(1), 3–10 (2005).
   PubMed Web of Science ®Google Scholar
• Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature353(6346), 765–769 (1991).
   PubMed Web of Science ®Google Scholar
• Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature337(6207), 562–566 (1989).
   PubMed Web of Science ®Google Scholar
• Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med.177(4), 1009–1020 (1993).
   PubMed Web of Science ®Google Scholar
• Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med.177(4), 999–1008 (1993).
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Crosbie J, Adelstein S et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature334(6184), 676–682 (1988).
   PubMed Web of Science ®Google Scholar
• Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science301(5638), 1374–1377 (2003).
   PubMed Web of Science ®Google Scholar
• Spohn G, Bachmann MF. Therapeutic vaccination to block receptor-ligand interactions. Expert Opin. Biol. Ther.3(3), 469–476 (2003).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest.108(3), 415–423 (2001).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol.169(11), 6120–6126. (2002).
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol.32(11), 3305–3314 (2002).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov.3(1), 81–88 (2004).
   PubMed Web of Science ®Google Scholar
• Janus C, Pearson J, McLaurin J et al. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature408(6815), 979–982 (2000).
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE et al. A β peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature408(6815), 982–985 (2000).
   Google Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740), 173–177 (1999).
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron38(4), 547–554 (2003).
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med.9(4), 448–452 (2003).
   PubMed Web of Science ®Google Scholar
• Zamora E, Handisurya A, Shafti-Keramat S et al. Papillomavirus-like particles are an effective platform for amyloid-β immunization in rabbits and transgenic mice. J. Immunol.177(4), 2662–2670 (2006).
   PubMed Web of Science ®Google Scholar
• Greenstone HL, Nieland JD, de Visser KE et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA95(4), 1800–1805 (1998).
   PubMed Web of Science ®Google Scholar
• Tegerstedt K, Lindencrona JA, Curcio C et al. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res.65(13), 5953–5957 (2005).
   PubMed Web of Science ®Google Scholar
• Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc. Natl Acad. Sci. USA94(14), 7503–7508. (1997).
   PubMed Web of Science ®Google Scholar
• Kang SM, Yao Q, Guo L, Compans RW. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J. Virol.77(18), 9823–9830 (2003).
   PubMed Web of Science ®Google Scholar
• Skountzou I, Quan FS, Gangadhara S et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte–macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J. Virol.81(3), 1083–1094 (2007).
   PubMed Web of Science ®Google Scholar
• Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol.172(3), 1777–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology290(2), 350–360 (2001).
   PubMed Web of Science ®Google Scholar
• Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine21(23), 3219–3227 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarz K, Meijerink E, Speiser DE et al. Efficient homologous prime–boost strategies for T cell vaccination based on virus-like particles. Eur. J. Immunol.35(3), 816–821 (2005).
   PubMed Web of Science ®Google Scholar
• Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J. Virol.79(2), 717–724 (2005).
   PubMed Web of Science ®Google Scholar
• Clarke BE, Newton SE, Carroll AR et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature330(6146), 381–364 (1987).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet366(9502), 2012–2018 (2005).
   PubMed Web of Science ®Google Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun.73(6), 3587–3597 (2005).
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun.72(11), 6519–6527 (2004).
   PubMed Web of Science ®Google Scholar
• Walther M, Dunachie S, Keating S et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine23(7), 857–864 (2005).
   PubMed Web of Science ®Google Scholar
• Kundig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol.117(6), 1470–1476 (2006).
   PubMed Web of Science ®Google Scholar
• Dyer MR, Renner WA, Bachmann MF. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov. Today11(21–22), 1028–1033 (2006).
   PubMed Web of Science ®Google Scholar
• Milich DR, Peterson DL, Zheng J, Hughes JL, Wirtz R, Schodel F. The hepatitis nucleocapsid as a vaccine carrier moiety. Ann. NY Acad. Sci.754, 187–201 (1995).
   PubMed Web of Science ®Google Scholar
• Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology44(2–3), 98–114 (2001).
   PubMed Web of Science ®Google Scholar
• Slupetzky K, Shafti-Keramat S, Lenz P et al. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J. Gen. Virol.82(Pt 11), 2799–2804 (2001).
   PubMed Web of Science ®Google Scholar
• Ionescu RM, Przysiecki CT, Liang X et al. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J. Pharm. Sci.95(1), 70–79 (2006).
   PubMed Web of Science ®Google Scholar
• Nieland JD, Da Silva DM, Velders MP et al. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J. Cell. Biochem.73(2), 145–152 (1999).
   PubMed Web of Science ®Google Scholar
• Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology273(2), 374–382 (2000).
   PubMed Web of Science ®Google Scholar
• Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology240(1), 147–157 (1998).
   PubMed Web of Science ®Google Scholar
• Amexis G, Young NS. Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus. J. Infect. Dis.194(6), 790–794 (2006).
   PubMed Web of Science ®Google Scholar
• Ogasawara Y, Amexis G, Yamaguchi H, Kajigaya S, Leppla SH, Young NS. Recombinant viral-like particles of parvovirus B19 as antigen carriers of anthrax protective antigen. In vivo20(3), 319–324 (2006).
   PubMed Web of Science ®Google Scholar
• Porta C, Spall VE, Lin T, Johnson JE, Lomonossoff GP. The development of cowpea mosaic virus as a potential source of novel vaccines. Intervirology39(1–2), 79–84 (1996).
   PubMed Web of Science ®Google Scholar
• Brennan FR, Gilleland LB, Staczek J, Bendig MM, Hamilton WD, Gilleland HE Jr. A chimaeric plant virus vaccine protects mice against a bacterial infection. Microbiology145(Pt 8), 2061–2067 (1999).
   PubMed Web of Science ®Google Scholar
• Dalsgaard K, Uttenthal A, Jones TD et al. Plant-derived vaccine protects target animals against a viral disease. Nat. Biotechnol.15(3), 248–252 (1997).
   PubMed Web of Science ®Google Scholar
• Marusic C, Rizza P, Lattanzi L et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol.75(18), 8434–8439 (2001).
   PubMed Web of Science ®Google Scholar
• Smith ML, Lindbo JA, Dillard-Telm S et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology348(2), 475–488 (2006).
   PubMed Web of Science ®Google Scholar
• McCormick AA, Corbo TA, Wykoff-Clary S et al. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. Vaccine24(40–41), 6414–6423 (2006).
   PubMed Web of Science ®Google Scholar
• Mastico RA, Talbot SJ, Stockley PG. Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid. J. Gen. Virol.74(Pt 4), 541–548 (1993).
   PubMed Web of Science ®Google Scholar
• Adams SE, Burns NR, Layton GT, Kingsman AJ. Hybrid Ty virus-like particles. Int. Rev. Immunol.11(2), 133–41 (1994).
   PubMedGoogle Scholar
• Sonderegger I, Rohn TA, Kurrer MO et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol.36(11), 2849–2856 (2006).
   PubMed Web of Science ®Google Scholar
• Ambuhl PM, Tissot AC, Fulurija A et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertens.25(1), 63–72 (2007).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J. Virol.78(8), 4037–4047 (2004).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl Acad. Sci. USA96, 2373–2378 (1999).
   PubMed Web of Science ®Google Scholar
• Spohn G, Schwarz K, Maurer P et al. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J. Immunol.175(9), 6211–6218 (2005).
   PubMed Web of Science ®Google Scholar
• Gathuru JK, Koide F, Ragupathi G et al. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity. Vaccine23(39), 4727–4733 (2005).
   PubMed Web of Science ®Google Scholar